

State/Territory: Commonwealth of Pennsylvania STANDARDS FOR THE COVERAGE OF
ORGAN TRANSPLANT SERVICES

(ii) Continued

Heart/Lung

Severe, irreversible, benign lung disease with secondary cardiac failure where lung transplant alone would not restore adequate cardiac function.

Lung

Single - Severe, irreversible, benign lung disease that is severely restricting activities of daily living and no longer amenable to standard medical treatment. Cardiac failure may or may not be present.

Double - Severe, irreversible, benign lung disease that is severely restricting activities of daily living and no longer amenable to standard medical treatment. The significant factor is the presence of a disease that typically includes infection of a chronic nature, for example, Cystic Fibrosis.

Liver

End Stage Liver Disease, non-malignant in etiology.

1. Acute, fulminant liver necrosis/failure such as seen in certain toxic states, for example, acetaminophen ingestion in toxic amounts.

2. Chronic liver failure where the complications of encephalopathy for ascites and/or variceal bleeding or other complications are no longer amenable to or controlled by recognized medical management.

Pancreas

Type I Insulin Dependent Diabetes Mellitus (IDDM) secondary to traumatic or surgical removal of the pancreas where alternative medical management is no longer possible in order to permit reasonable activities of daily living. Suitable documentation showing this status

IN # 93-10
Supersedes
IN # New

Approval Date _____

Effective Date Jan. 1, 1993
HCFA ID: 1000000047P/0016P

State/Territory: Commonwealth of Pennsylvania

STANDARDS FOR THE COVERAGE OF ORGAN TRANSPLANT SERVICES

(E) continued

Pancreas continued

must be provided. The presence of associated progressive life threatening complications of Type I IDDM, such as retinopathy and peripheral vascular disease, would impact consideration and would have to be individually evaluated.

Bone Marrow

For the treatment of certain diseases where it has come to represent a standard approach to treatment of the disease such as lymphomas and leukemias. Not approved for the treatment of diseases which the Department considers to still be of an investigative or research nature.

TX # 93-10
Supersedes
TX # New

Approval Date _____

Effective Date Jan. 1, 1993
HCFA ID: 1047P/0016P